XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
T
T

ThermoFisher


Haberler

Thermo Fisher Scientific Declares Quarterly Dividend

BRIEF-Thermo Fisher Scientific Declares Quarterly Dividend July 11 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC INC - AUTHORIZED A QUARTERLY CASH DIVIDEND OF $0.39 PER COMMON SHARE Source text for Eikon: ID:nBw5nbtna Further company coverage: TMO.N
T

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

BRIEF-Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology July 11 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC TO HELP ADVANCE MYELOID CANCER CLINICAL RESEARCH AND TREATMENT UTILIZING NEXT GENERATION SEQUENCING TECHNOLOGY THERMO FISHER S
T

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Petrobras, Envestnet, Metro Bank; Updates Eli Lilly, Masimo July 8 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1 945 GMT on Monday: * * Brazilian logistics firm Transpetro, a unit of state-run oil firm Petrobras PETR4.SA , said it has launched a procurement notice to commission four new coastal vessels, which it hopes will help revive the nation's shipbuilding sector.
B
G
T

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Masimo, Devon Energy, Vista Outdoor, Eli Lilly, Thermo Fisher Scientific's Updates: Paramount Global, Carlsberg, Grifols July 8 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Masimo MASI.O said a potential partner is prepared to offer $850 million to $950 million for its consumer business.
B
G
T

Olink Announces Receipt Of CMA Clearance For Proposed Acquisition By Thermo Fisher

BRIEF-Olink Announces Receipt Of CMA Clearance For Proposed Acquisition By Thermo Fisher July 8 (Reuters) - Olink Holding AB (publ) OLK.O : OLINK ANNOUNCES RECEIPT OF CMA CLEARANCE FOR PROPOSED ACQUISITION BY THERMO FISHER Source text for Eikon: ID:nGNXZwSkq Further company coverage: OLK.O
T

UK's competition regulator clears $3.1 bln Thermo Fisher Scientific-Olink deal

UK's competition regulator clears $3.1 bln Thermo Fisher Scientific-Olink deal July 8 (Reuters) - UK's competition regulator said on Monday it has cleared U.S. medical equipment maker Thermo Fisher Scientific's TMO.N $3.1 billion deal to buy Swedish biotech firm Olink Holding AB OLK.O . Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Sh
T

Thermo Fisher Scientific Expands Clinical Research Laboratory In Kentucky

BRIEF-Thermo Fisher Scientific Expands Clinical Research Laboratory In Kentucky Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXPANDS CLINICAL RESEARCH LABORATORY IN KENTUCKY THERMO FISHER SCIENTIFIC : $47.8 MILLION INVESTMENT IS EXPECTED TO CREATE MORE THAN 250 NEW JOBS ACROSS TWO SITES OVER NEXT EIGHT YEARS Source text for Eikon:
T

U.S. CarMax, Eli Lilly, MicroStrategy

U.S. RESEARCH ROUNDUP-CarMax, Eli Lilly, MicroStrategy June 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CarMax, Eli Lilly and MicroStrategy, on Monday. HIGHLIGHTS * CarMax Inc KMX.N : RBC raises target price to $75 from $73 * Eli Lilly LLY.N : Jefferies raises target price to $1,015 from $994 * MicroStrategy Inc MSTR.O : Canaccord Genuity cuts target price to $1,826 from $2,047 * Sharecare Inc SHCR.O : Canacco
A
A
B
D
G
M
N
V
E
F
T
E
P
R
T
C
C
I

Sarepta surges on FDA's expanded use nod for company's Duchenne gene therapy

BUZZ-Sarepta surges on FDA's expanded use nod for company's Duchenne gene therapy ** Shares of Sarepta Therapeutics SRPT.O surged about 33% to a more than three-year high in early trade ** At current levels, nearly $4 bln was set to be added to company's market value ** Late on Thursday, U.S. FDA granted traditional approval for company's gene therapy, Elevidys, for patients with inherited progressive muscle-wasting disorder ** Agency's nod allows use in kids aged four-year and above who can wal
T

Sarepta surges as investors cheer expanded use of gene therapy

UPDATE 2-Sarepta surges as investors cheer expanded use of gene therapy Adds background on FDA decision in paragraph 4, CEO quote in paragraphs 8 & 9, analyst quote in paragraph 12 & 13 By Mariam Sunny and Bhanvi Satija June 21 (Reuters) - Sarepta Therapeutics SRPT.O shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for Duchenne muscular dystrophy (DMD).
N
P
T

Thermo Fisher Scientific Expands Clinical Research Laboratory In Wisconsin

BRIEF-Thermo Fisher Scientific Expands Clinical Research Laboratory In Wisconsin June 18 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXPANDS CLINICAL RESEARCH LABORATORY IN WISCONSIN Source text for Eikon: ID:nBw21nSLsa Further company coverage: TMO.N
T

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions To Comply With IVDR Regulation

BRIEF-Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions To Comply With IVDR Regulation May 31 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC UPDATES CHROMOSOMAL MICROARRAY ANALYSIS SOLUTIONS TO COMPLY WITH IVDR REGULATION THERMO FISHER SCIENTIFIC INC: APPLIED BIOSYSTEMS™ CYTOSCAN™ DX AND CHROM
T

Bluebird bio appoints new CFO to oversee financial restatements

UPDATE 2-Bluebird bio appoints new CFO to oversee financial restatements Adds background throughout May 29 (Reuters) - Gene therapy maker bluebird bio BLUE.O on Wednesday named former Renalytix RENX.L finance chief James Sterling as its CFO to oversee the revision of the company's financial statements. Sterling will take over on June 10 from incumbent Chris Krawtschuk, who was in the role from November 2022. The company announced its plans to revise its financial statements in March, citing "mat
G
T

Ultragenyx must face Henrietta Lacks family lawsuit over HeLa cell profits

CORRECTED-Ultragenyx must face Henrietta Lacks family lawsuit over HeLa cell profits Corrects Ultragenyx attorneys' law firm information By Blake Brittain May 20 (Reuters) - The estate of Henrietta Lacks can move forward with a lawsuit against biopharmaceutical company Ultragenyx RARE.O over the use of cells taken from Lacks' body in the 1950s, a Maryland federal court said on Monday.
T

UK's CMA kicks off probe into Thermo Fisher-Olink deal

UK's CMA kicks off probe into Thermo Fisher-Olink deal May 10 (Reuters) - Britain's competition regulator said on Friday it has initiated a probe into U.S. medical equipment maker Thermo Fisher Scientific's TMO.N $3.1 billion deal to buy Swedish biotech firm Olink Holding AB OLK.O . The Competition and Markets Authority (CMA) has set a deadline of July 8 for its phase 1 decision.
T

UK's CMA Starts Merger Investigation Into Thermo Fisher/Olink Deal

BRIEF-UK's CMA Starts Merger Investigation Into Thermo Fisher/Olink Deal May 10 (Reuters) - Competition and Markets Authority (CMA): START OF CMA MERGER INVESTIGATION: THERMO FISHER SCIENTIFIC / OLINK DEADLINE OF 08 JULY 2024 FOR ITS PHASE 1 DECISION. FOR THERMO FISHER/OLINK DEAL Source text for Eikon: ID:nRSJ8561Na Further company coverage: TMO.N
T

Waters Corp beats quarterly estimates on strong demand for drug development services

Waters Corp beats quarterly estimates on strong demand for drug development services May 7 (Reuters) - Waters Corp WAT.N beat Wall Street estimates for first-quarter results on Tuesday, helped by strong demand for its services used in drug development and research. Drug contract manufacturers such as Waters saw reduced spending from their biotech clients last year due to higher interest rates.
T
W

Becton Dickinson lifts profit view on strong surgical equipment demand

Becton Dickinson lifts profit view on strong surgical equipment demand May 2 (Reuters) - Becton Dickinson BDX.N raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes. Medical technology firms like Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, undergo surgeries that were put on hold during the
A
B
T

Anti-obesity drugmakers savor pandemic leftovers

BREAKINGVIEWS-Anti-obesity drugmakers savor pandemic leftovers The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, May 1 (Reuters Breakingviews) - Eli Lilly LLY.N and Novo Nordisk NOVOb.CO have a luxury problem, one they’re solving quickly. The two drugmakers worth a combined $1.2 trillion cannot produce enough of their injectable anti-obesity treatments to meet extraordinary demand.
B
T

Thermo Fisher Scientific Extends Expiration Of Tender Offer

BRIEF-Thermo Fisher Scientific Extends Expiration Of Tender Offer May 1 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXTENDS THE EXPIRATION OF TENDER OFFER FOR ALL OUTSTANDING COMMON SHARES AND ADSS OF OLINK THERMO FISHER SCIENTIFIC INC - OFFER NOW SCHEDULED TO EXPIRE AT 5:00 P.M., NEW YORK TIME, ON JUNE 18, 2024 Source
T



Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.